Scientific Publications

Legend Biotech sponsors research with academic institutions to evaluate our agents. The manuscripts from this research are presented below.

Year :

Comprehensive BCMA Expression Profiling in Adult Normal Human Brain Suggests a Low Risk of On-target Neurotoxicity in BCMA-targeting Multiple Myeloma Therapy

M Marella, X Yao, V Carreira, MF Bustamante, HB Clark, CC Jackson, E Zudaire, JM Schecter, TD Glover, J Shenton, I Cornax

The Patient Experience of Relapsed Refractory Multiple Myeloma and Perspectives on Emerging Therapies

R Crawford, KS Gries, S Valluri, J Fastenau, R Morrison, T-M Yeh, Y Olyslager, JD Goldberg, JM Schecter, CJ Jackson, W Deraedt, L Doward

Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry

M Merz, H Goldschmidt, P Hari, M Agha, J Diels, F Ghilotti, NJ Perualila, J Cabrieto, B Haefliger, H Sliwka, JM Schecter, CC Jackson, Y Olyslager, M Akram, T Nesheiwat, L Kellermann, S Jagannath

Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE‑1 vs Physician’s Choice of Therapy in the Long‑Term Follow‑Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

K Weisel, T Martin, A Krishnan, S Jagannath, A Londhe, S Nair, J Diels, M Vogel, JM Schecter, A Banerjee, JG Berdeja, T Nesheiwat, A Garrett, K Qi, S Valluri, SZ Usmani, K Yong

Healthcare Costs Incurred by Patients with Multiple Myeloma Following Triple Class Exposure (TCE) in the US

S Jagannath, N Joseph, J He, C Crivera, AZ Fu, A Garrett, N Shah